1. Treatment of lung adenocarcinoma by molecular-targeted therapy and immunotherapy
- Author
-
Motonobu Saito, Seiichi Takenoshita, Hiroyuki Suzuki, Koji Kono, and Takashi Kohno
- Subjects
Male ,Proto-Oncogene Proteins B-raf ,0301 basic medicine ,Lung Neoplasms ,Receptor, ErbB-2 ,medicine.medical_treatment ,Adenocarcinoma ,medicine.disease_cause ,Targeted therapy ,Proto-Oncogene Proteins p21(ras) ,03 medical and health sciences ,0302 clinical medicine ,Surgical oncology ,Proto-Oncogene Proteins ,ROS1 ,Humans ,Medicine ,Anaplastic Lymphoma Kinase ,Genetic Testing ,Molecular Targeted Therapy ,Precision Medicine ,Chromosome Aberrations ,business.industry ,Gene Drive Technology ,Proto-Oncogene Proteins c-ret ,Receptor Protein-Tyrosine Kinases ,Cancer ,General Medicine ,Immunotherapy ,Protein-Tyrosine Kinases ,medicine.disease ,Immune checkpoint ,ErbB Receptors ,030104 developmental biology ,030220 oncology & carcinogenesis ,Mutation ,Cancer research ,Female ,Surgery ,KRAS ,Gene Fusion ,business - Abstract
Lung adenocarcinoma (LADC) is a cancer treatable using targeted therapies against driver gene aberrations. EGFR mutations and ALK fusions are frequent gene aberrations in LADC, and personalized therapies against those aberrations have become a standard therapy. These targeted therapies have shown significant positive efficacy and tolerable toxicity compared to conventional chemotherapy, so it is necessary to identify additional druggable genetic aberrations. Other than EGFR mutations and ALK fusions, mutations in KRAS, HER2, and BRAF, and driver fusions involving RET and ROS1, have also been identified in LADC. Interestingly, the frequency of driver gene aberrations differs according to ethnicity, sex, and smoking, which leads to differences in treatment efficacy. To date, several molecular-targeted drugs against driver genes have been developed, and several clinical trials have been conducted to evaluate the efficacy. However, targeted therapies against driver-gene-negative cases have not yet been well developed. Efforts to identify a new druggable target for such cases are currently underway. Furthermore, immune checkpoint blockade therapy might be effective for driver-negative cases, especially those with accumulated mutations.
- Published
- 2017
- Full Text
- View/download PDF